Table 2. Modified Intention-to-Treat Analysis Comparing Atopic Eczema and Asthma Outcomes in Intervention vs Control Group.
| Variable | No. (%) | OR (95% CI) | ||
|---|---|---|---|---|
| Intervention (n = 7064) | Control (n = 6493) | Cluster Adjusted | Further Adjusteda | |
| Atopic eczema | ||||
| Flexural eczema on skin examination | 21 (0.3) | 43 (0.7) | 0.46 (0.25 to 0.86) | 0.46 (0.25 to 0.83) |
| Flexural eczema past year | 32 (0.5) | 45 (0.7) | 0.57 (0.27 to 1.18) | 0.55 (0.27 to 1.14) |
| Persistent flexural eczema past year | 10 (0.1) | 19 (0.3) | 0.48 (0.22 to 1.04) | 0.47 (0.22 to 1.03) |
| Sleep-disturbed flexural eczema past year | 13 (0.2) | 24 (0.4) | 0.54 (0.23 to 1.28) | 0.55 (0.22 to 1.39) |
| Asthma | ||||
| Ever asthma | 108 (1.5) | 110 (1.7) | 0.76 (0.47 to 1.23) | 0.77 (0.47 to 1.24) |
| Wheezing in past 12 mo | 431 (6.1) | 419 (6.5) | 0.66 (0.37 to 1.18) | 0.61 (0.34 to 1.07) |
| Asthma attack in past 12 mo | 29 (0.4) | 24 (0.4) | 1.01 (0.54 to 1.89) | Did not converge |
Abbreviation: OR, odds ratio.
a
Adjusted for stratum-level variables (urban vs rural and East vs West Belarus), and for child age at follow-up, sex, birthweight, and maternal and paternal education. Asthma and lung function models were also adjusted for gestational age at birth.